| A Study of AK-1286 in Patients With Advanced Solid Tumors (NCT06779045) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2025-02-01 |
| YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer (NCT06662669) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2024-11-30 |
| A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma (NCT06548347) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2024-09-10 |
| A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma (NCT06343935) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2024-04-30 |
| A Study of HY-0102 in Patients With Advanced Solid Tumors (NCT06094777) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2023-12-18 |
| Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS (NCT06096974) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2023-10-24 |
| A Study of YL-17231 in Patients With Advanced Solid Tumors (NCT06078800) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2023-09-28 |
| A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor (NCT06026501) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2023-08-31 |
| A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors (NCT05457517) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2022-09-24 |
| A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor (NCT05429398) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2022-06-30 |
| A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma (NCT05274997) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2022-05-01 |
| A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation (NCT05119933) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2021-11-09 |
| A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer (NCT04975061) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2021-08-01 |
| A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma (NCT04705090) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2021-04-01 |
| A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma (NCT04379167) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-12-30 |
| YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial (NCT04500561) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-08-20 |
| A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies (NCT04279405) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-06-15 |
| A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT04108325) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-03-30 |
| A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors (NCT04049929) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2019-08-01 |
| A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma (NCT04370405) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2019-04-29 |
| First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors (NCT03869632) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2019-03-19 |